Mycophenolate mofetil and Ozurdex drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mycophenolate mofetil (mycophenolate mofetil) and Ozurdex (dexamethasone). Common drug interactions include rebound effect among females and intraocular pressure increased among males.

The phase IV clinical study analyzes what interactions people have when they take Mycophenolate mofetil and Ozurdex. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Mycophenolate mofetil?

Mycophenolate mofetil has active ingredients of mycophenolate mofetil. It is often used in myasthenia gravis. eHealthMe is studying from 93,461 Mycophenolate mofetil users. Check the latest studies of Mycophenolate mofetil.

What is Ozurdex?

Ozurdex has active ingredients of dexamethasone. eHealthMe is studying from 2,497 Ozurdex users. Check the latest studies of Ozurdex.



On Aug, 03, 2026

21 people who take Mycophenolate mofetil and Ozurdex together, and have interactions are studied.

Mycophenolate mofetil and Ozurdex drug interactions.

What are the common drug interactions of Mycophenolate Mofetil and Ozurdex, by gender? *:

female:

  1. Rebound effect (take-back effect)
  2. Cystoid macular oedema (fluid accumulation after cataract surgery)
  3. Drug ineffective
  4. Retinal vasculitis (a sight-threatening inflammatory eye condition that involves the retinal vessels)
  5. Retinal vein occlusion (a blockage of the small veins that carry blood away from the retina)
  6. Vision blurred

male:

  1. Intraocular pressure increased
  2. Uveitis (inflammation of the uvea)
  3. Conjunctival haemorrhage (bleeding underneath the conjunctiva)
  4. Cushingoid (obesity and weakening of the muscles)
  5. Cytomegalovirus chorioretinitis (infection of choroid and retina of the eye from virus)
  6. Depressive symptom
  7. Hypotonia (low muscle tone)
  8. Papillitis (inflammation of the optic nerve head)
  9. Vitreous floaters (spots before the eyes)
  10. Vitritis (inflammation of the vitreous humour of the eye)

What are the common drug interactions of Mycophenolate Mofetil and Ozurdex, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Choroiditis (infection of vascular layer of eye)
  2. Drug ineffective
  3. Endophthalmitis (inflammation of the internal coats of the eye)
  4. Eye pain
  5. Intraocular pressure increased
  6. Uveitis (inflammation of the uvea)
  7. Visual acuity reduced (reduced clearness of vision)
  8. Chondritis (inflammation of cartilage)
  9. Visual impairment
  10. Cystoid macular oedema (fluid accumulation after cataract surgery)

40-49:

n/a

50-59:

  1. Abdominal pain
  2. Glucose tolerance impaired (blood glucose is raised beyond normal levels, but not high enough to warrant a diabetes diagnosis)
  3. Troponin i increased
  4. Infectious peritonitis (inflammation of the peritoneum, typically caused by bacterial infection)
  5. Intraocular pressure increased
  6. Large intestine carcinoma (cancer of large intestine)
  7. Large intestine perforation (hole in large intestine)
  8. Lymphoedema (localized fluid retention and tissue swelling)
  9. Metastases to liver (cancer spreads to liver)
  10. Metastases to lymph nodes (cancer spreads to lymph node)

60+:

n/a

What are the existing conditions these people have? *

  1. Uveitis (inflammation of the uvea): 11 people, 52.38%
  2. Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 8 people, 38.10%
  3. Iridocyclitis (inflammation of the iris and ciliary body of the eye): 8 people, 38.10%
  4. Endophthalmitis (inflammation of the internal coats of the eye): 8 people, 38.10%
  5. Retinal Vasculitis (a sight-threatening inflammatory eye condition that involves the retinal vessels): 5 people, 23.81%
  6. Cystoid Macular Oedema (fluid accumulation after cataract surgery): 5 people, 23.81%
  7. Angiopathy (generic term for a disease of the blood vessels): 3 people, 14.29%
  8. Retinal Vessel Occlusion (a blockage in one of the small arteries): 2 people, 9.52%
  9. Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Mycophenolate mofetil and Ozurdex?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mycophenolate mofetil and Ozurdex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mycophenolate mofetil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ozurdex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mycophenolate mofetil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ozurdex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on mycophenolate mofetil and dexamethasone (the active ingredients of Mycophenolate mofetil and Ozurdex, respectively), and Mycophenolate mofetil and Ozurdex (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: